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Background: Axitinib is an orally active and potent tyrosine kinase inhibitor of vascular endothelial growth factor
receptors 1, 2 and 3. This phase II study assessed the efficacy and safety of axitinib combined with cisplatin/gemcitabine
in chemotherapy-naïve patients with advanced/metastatic (stage IIIB/IV) squamous non–small-cell lung cancer (NSCLC).
Methods: Axitinib (starting dose 5 mg twice daily [bid]; titrated up or down to 2–10 mg bid) was administered orally on
a continuous schedule with cisplatin (80 mg/m2 intravenously [i.v.] every 3 weeks) and gemcitabine (1,250 mg/m2 i.v. on
days 1 and 8 of each 3-week cycle), and was continued as monotherapy after completion of six cycles (maximum) of
chemotherapy. The primary study endpoint was objective response rate, as defined by Response Evaluation Criteria in
Solid Tumours.
Results: Of the 38 patients treated, one (2.6%) patient achieved a complete response and 14 (36.8%) patients had a
partial response; nine (23.7%) patients showed stable disease and three (7.9%) patients had disease progression. Median
progression-free survival was 6.2 months, and median overall survival was 14.2 months. The estimated probability of
survival at 12 months and 24 months was 63.2% and 30.8%, respectively. The most frequent grade ≥3 toxicities were
neutropaenia and hypertension (13.2% each). Three (7.9%) patients experienced haemoptysis, of which one case (2.6%)
was fatal.
Conclusions: Treatment with the combination of axitinib and cisplatin/gemcitabine demonstrated anti-tumour activity
in patients with advanced/metastatic squamous NSCLC and the fatal haemoptysis rate was low. However, without a
reference arm (cisplatin/gemcitabine alone), it is not conclusive whether the combination is better than chemotherapy
alone. This study was registered at ClinicalTrials.gov, registration # NCT00735904, on August 13, 2008.
Keywords: Non–small-cell lung cancer, Squamous cell, Axitinib, Anti-angiogenic treatment, Platinum-based
chemotherapy, Phase IIBackground
Non–small-cell lung cancer (NSCLC), a heterogeneous
group of histologies that includes adenocarcinoma, squa-
mous cell carcinoma and large cell carcinoma, accounts for
approximately 85% of all lung cancers [1]. Patients with
NSCLC typically present with locally advanced or meta-
static disease at the time of diagnosis [2], and in these cases
prognosis is poor, with a 5-year survival rate of less than
10% [3].* Correspondence: oncology@dsma.dp.ua
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unless otherwise stated.Platinum-based double-agent chemotherapy, which is
standard first-line treatment for most patients with stage
IIIB or IV NSCLC, is associated with an objective response
rate of 17–38% and a median survival time of approxi-
mately 7 to 14 months [4-10]. Clinical evidence indicates
that there are minimal differences in efficacy (objective
response rate and overall survival) between the various
platinum-based doublet regimens in the treatment of
advanced NSCLC [11,12], and that the addition of a third
cytotoxic agent increases toxicity but does not prolong sur-
vival [13]. Thus, it would appear that standard cytotoxic
chemotherapy has reached a therapeutic plateau in
advanced NSCLC [14]. As a consequence, current researchntral. This is an Open Access article distributed under the terms of the Creative
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angiogenic agent to double-agent chemotherapy [15,16].
Vascular endothelial growth factor (VEGF) is a key
molecular target in the treatment of NSCLC [17,18],
and the combination of VEGF-directed anti-angiogenic
therapy with platinum-based doublet chemotherapy
offers potential for improved outcomes in advanced
NSCLC [15,19,20]. Bevacizumab, a recombinant huma-
nised anti-VEGF monoclonal antibody with a plasma
half-life of approximately 3 weeks [21], was the first
anti-angiogenic agent to show a survival benefit when
combined with standard cytotoxic chemotherapy in ad-
vanced non-squamous NSCLC, extending median over-
all survival beyond 12 months [22]. However, the use of
bevacizumab is restricted by the risk of high-grade
bleeding [23], including potentially fatal pulmonary
haemorrhage [24], particularly among patients with
squamous NSCLC [25]. Phase II evidence implicating
squamous histology as a risk factor for bevacizumab-
induced pulmonary haemorrhage [26] resulted in exclu-
sion of patients with squamous NSCLC from subsequent
clinical trials. Accordingly, bevacizumab is only approved
for the treatment of non-squamous NSCLC [27]. Ramu-
cirumab, a human monoclonal antibody targeting the
VEGF receptor 2, has been recently approved by the US
Food and Drug Administration as an add-on therapy for
metastatic NSCLC. Ramucirumab plus docetaxel im-
proved overall survival and progression-free survival
compared with placebo plus docetaxel in patients with
NSCLC whose disease progress after first-line treatment.
Bleeding/haemorrhage events of any grade occurred
more in the ramucirumab group compared with the pla-
cebo group; however, grade 3 or worse pulmonary haem-
orrhage did not differ between groups [28].
Axitinib (Inlyta®; Pfizer Inc, New York, NY, USA) is an
orally active and potent small-molecule tyrosine kinase in-
hibitor that produces broad inhibition of the VEGF path-
way by targeting all three VEGF receptor subtypes
(VEGFR1, VEGFR2 and VEGFR3) and has a short plasma
half-life of 2 to 5 hours [29]. Axitinib shows evidence of
single-agent activity in advanced NSCLC [30], and accept-
able toxicity, both as monotherapy [30,31] and when
combined with chemotherapy, including cisplatin plus
gemcitabine or carboplatin plus paclitaxel [32]. The
objective of this phase II study was to assess the safety
and efficacy of axitinib in combination with cisplatin




Patients aged ≥18 years with histologically or cytologically
confirmed squamous NSCLC that was locally advanced
(stage IIIB) with pleural effusion or metastatic (stage IV)or recurrent, and with measurable disease by Response
Evaluation Criteria in Solid Tumours (RECIST) [33]
were eligible for study inclusion. Patients were required
to have an Eastern Cooperative Oncology Group per-
formance status of 0 or 1, adequate renal and hepatic
function and adequate bone marrow reserve (absolute
neutrophil count ≥1,500 cells/μL, platelets ≥100,000
cells/μL). Patients were excluded from the study if they
had received prior systemic therapy for stage IIIB/IV
NSCLC (prior surgery or radiotherapy was permitted if
completed ≥4 and ≥3 weeks, respectively, before enrol-
ment) or prior anti-VEGF therapy; had lung lesions with
cavitation or major blood vessel involvement, uncon-
trolled brain metastases or seizures, active malignancies
other than NSCLC, gastrointestinal abnormalities or
uncontrolled hypertension (systemic blood pressure [BP]
>140/90 mm Hg); had experienced cardiovascular/
cerebrovascular disease, bleeding diathesis or coagu-
lopathy within 12 months of study entry or epileptic
seizures or grade ≥3 haemoptysis/haemorrhage within
4 weeks of study entry; or had current or anticipated
use of anti-coagulants or drugs known to be potent
cytochrome P450 (CYP) 3A4 inhibitors or CYP1A2 or
CYP3A4 inducers.
Study design and treatment
This open-label, single-arm study was conducted at 10
centres in Poland, Romania, Ukraine and South Africa,
from 17 December 2008 to 30 November 2011. The
primary study endpoint was objective response rate, as
defined by RECIST criteria; secondary endpoints
included progression-free survival, overall survival, dur-
ation of response and safety. Progression-free survival
was defined as the time from commencement of study
medication to documentation of disease progression or
death, whichever occurred first. Overall survival was
defined as the time from commencement of study medica-
tion to death from any cause. Duration of response was de-
fined as the time from first documentation of response to
documentation of disease progression or death, whichever
occurred first.
The study was approved by the independent ethics
committee at each participating centre (see Additional
file 1: Table S1) and was conducted in accordance with
the Declaration of Helsinki and relevant International
Conference on Harmonisation Good Clinical Practice
guidelines. Written informed consent was obtained from
all patients before entry into the study. The study is listed
in the US National Institutes of Health ClinicalTrials.gov
registry under the identifier NCT00735904 [34].
All patients received standard platinum-based doublet
chemotherapy (cisplatin/gemcitabine) plus axitinib. Cis-
platin (80 mg/m2 intravenous infusion) was administered
on day 1 and gemcitabine (1,250 mg/m2 intravenous
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therapy, for a maximum of six cycles. Axitinib was ad-
ministered orally on a continuous schedule at a starting
dose of 5 mg twice daily (bid) and was continued as
maintenance therapy after completion of chemotherapy
until disease progression. The starting dose for axitinib
(5 mg bid) was selected based on a phase I study of
axitinib in combination with cisplatin/gemcitabine that
indicated that a starting dose of 5-mg bid axitinib could
be safely combined with standard doses of cisplatin/
gemcitabine [32]. Axitinib could be up-titrated incre-
mentally to 7 mg bid and then to a maximum dose of
10 mg bid if the patient showed no treatment-related
grade ≥3 toxicity during 2 weeks of treatment with the
existing dose. Dose up-titration was not permitted if the
patient had a BP >150/90 mm Hg or was receiving anti-
hypertensive therapy. Chemotherapy dose reductions were
based on the maximum grade of haematological and non-
haematological toxicities observed during the previous
treatment cycle and on the day of initiation of the current
dose. Subsequent chemotherapy dose re-escalation was per-
mitted at the investigator’s discretion in the absence of
grade ≥3 haematological and grade ≥2 non-haematological
toxicities during the previous treatment cycle. Patients who
discontinued chemotherapy due to toxicity were allowed to
continue with axitinib monotherapy.
Stepwise reductions in axitinib dose from a starting
dose of 5-mg bid to a minimum of 2-mg bid were man-
dated by the occurrence of treatment-related toxicities
of grade ≥3 severity. In the event of marked hyperten-
sion (BP >160/105 mmHg), haemoptysis, proteinuria or
grade 4 toxicity, axitinib treatment was interrupted until
its resolution and restarted at a lower dose. Axitinib
treatment was permanently discontinued if patients
required axitinib dose reduction below 2-mg bid or dose
interruption for >4 weeks, or if they showed evidence of
nephrotic syndrome, lung cavitation or delayed (>1 week)
resolution of haemoptysis. Patients who discontinued
axitinib due to toxicity were allowed to continue with
scheduled chemotherapy. Concomitant administration of
potent CYP3A4/5 inhibitors and inducers, CYP1A2 and
CYP2C8 substrates, non-steroidal anti-inflammatory
drugs and coumarin-derivative anti-coagulants was dis-
couraged during the study. However, if usage of a potent
CYP3A4/5 inhibitor or inducer was necessary, agree-
ment had to be obtained from the study sponsor.
Study assessments
Tumour response was assessed by computed tomog-
raphy (CT) or magnetic resonance imaging at baseline
(within 28 days before commencing study treatment)
and was repeated every 6 weeks during chemotherapy
and every 8 weeks during axitinib maintenance therapy,
using RECIST criteria. Complete and partial tumourresponses were confirmed 4 weeks after first documenta-
tion. Physical examinations and serum chemistry and
urinalysis tests were performed at baseline, and were
repeated at 3- and 4-week intervals during chemother-
apy and axitinib maintenance therapy, respectively.
Haematology tests were performed at baseline, on days 1
and 8 of each cycle of chemotherapy and at 4-week in-
tervals during axitinib maintenance therapy. Patients
self-monitored their blood pressure bid during the study.
Patients were followed-up at 2-month intervals after the
final study visit to determine survival status. Patients
who were not known to be deceased at the time of data-
base closure were censored on the day when they were last
known to be alive. Adverse events (AEs) were graded for
severity using the National Cancer Institute Common
Terminology Criteria for Adverse Events, version 3.0 [35].
Statistical analyses
The study sample size (an accrual target of 36 patients)
was based on a single-stage design to test the null
hypothesis that the true objective response rate to treat-
ment was ≤40% versus the alternative hypothesis that
the true objective response rate was ≥60%, with type I
and II error levels of 0.10 and 0.15, respectively.
Efficacy and safety analyses were conducted on the
intent-to-treat (ITT) population, which comprised all
patients who received at least one dose of study medi-
cation. Descriptive statistics were used to summarise
continuous variables, and frequency and percentages
to summarise categorical variables. Two-sided 95%
confidence intervals (CI) for objective response rates
were calculated using the exact method based on the F
distribution. Time-to-event endpoints (overall survival,
progression-free survival and duration of response) were
estimated using Kaplan-Meier survival analysis. The
median time-to-event and 95% CI were determined for
each endpoint.
Results
Patient characteristics and treatment
A total of 38 chemotherapy-naïve patients with advanced
or metastatic squamous NSCLC were included in the study
and received at least one dose of study medication (ITT
population). Patients’ baseline demographics and clinical
characteristics are summarised in Table 1. The majority of
patients were white (97.4%), male (89.5%), had a history of
smoking (86.8%) and had stage IV disease (86.8%). Eighteen
(47%) patients received the maximum six cycles of com-
bined gemcitabine/cisplatin chemotherapy. The median
number of chemotherapy cycles started was 4 (range, 1–6).
The median duration of axitinib therapy was 3.1 (range,
0.2–22) months, and 17 (44.7%) patients went on to receive
axitinib maintenance therapy after chemotherapy. The
median dose of axitinib administered during the study was
Table 1 Baseline demographics and clinical characteristics of the ITT population
Characteristic Cisplatin + gemcitabine + axitinib (n = 38)
Age, years
Mean (SD) 60.5 (7.1)


















Prior surgery 17 (44.7)
Bronchoscopy 11 (28.9)
Lymph node/pleural biopsy 6 (15.8)
Lobectomy 2 (5.2)
Thoracic wall resection 1 (2.6)
Values are n (%) unless otherwise noted. ECOG, Eastern Cooperative Oncology Group; ITT, intent-to-treat; SD, standard deviation.
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(92.1%) of patients received concomitant medication during
the study, most commonly ondansetron, dexamethasone or
furosemide.
Efficacy
The investigator-assessed objective response rate
(complete and partial responses) for the ITT popula-
tion (n = 38) was 39.5% (95% CI, 24.0–56.6%). One
(2.6%) patient had a confirmed complete response and
14 (36.8%) patients had a confirmed partial response
on study medication; stable disease was reported in
nine (23.7%) patients and disease progression in three
(7.9%) patients (Table 2). Eight patients were ineligible
for assessment of tumour response since the scheduled
post-baseline CT scan was either unavailable or
performed >28 days after the last study dose. Two
further patients died before their first scheduled on-
study tumour assessment (week 6 of chemotherapy)
and one patient (excluded for protocol violation) did
not undergo baseline tumour assessment. The medianduration of response for patients with an objective
tumour response (n = 15) was 5.8 months (95% CI,
4.7–7.2 months).
Median progression-free survival after commence-
ment of study medication was 6.2 months (95% CI,
4.5–9.3 months) (Figure 1). Median overall survival was
14.2 months (95% CI, 11.8–23.1 months) (Figure 2).
The estimated probability of survival at 12 months and
24 months was 63.2% (95% CI, 44.7– 76.9%) and 30.8%
(95% CI, 15.5–47.7%), respectively. In total, 21 (55.3%)
patients died during the study (four patients during the
study treatment period and 17 patients during follow-
up).
Safety
A total of 36 (94.7%) patients reported at least one AE (all-
causality) of any grade, of which the most frequent were
nausea (42.1%), anaemia (31.6%), vomiting (28.9%), hyper-
tension (26.3%), neutropaenia (23.7%), weight loss (23.7%)
and decreased appetite (21.1%) (Table 3). The most com-
monly reported grade ≥3 AEs were neutropaenia
Table 2 Summary of tumour responses during the study period for the ITT population*
Tumour response, n (%) Cisplatin + gemcitabine + axitinib, (n = 38)
Complete response 1 (2.6)
Partial response 14 (36.8)
Stable disease 9 (23.7)
Progressive disease 3 (7.9)
Indeterminate response† 8 (21.1)
Not assessed due to early death‡ 2 (5.3)
Baseline status uncertain§ 1 (2.6)
Objective response (complete + partial) 15 (39.5)
ITT = intent-to-treat.
*Study period comprised the treatment period plus 28-day follow-up period after the last dose of study drug.
†Imaging scans unavailable or performed >28 days after the last study dose.
‡Death occurring before the first scheduled tumour assessment.
§No baseline assessment performed.
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fatigue (7.9%) (Table 3). Overall, 34 (89.5%) patients ex-
perienced treatment-related AEs (all grades). Fifteen
(39.5%) patients experienced serious AEs while on
treatment; the most frequent were anaemia, pneumo-
nia, dehydration and disease progression (n = 2 each
[5.3%]).
Fatal pulmonary haemorrhage is one of the major
safety concerns in patients receiving anti-angiogenic
therapy for squamous NSCLC. Three (7.9%) patients
had haemoptysis, including two patients with grade 1
severity and one patient with grade 5 severity. The latter
patient developed massive haemoptysis on day 16 of the
first treatment cycle and died later that day from
NSCLC; there was no prior evidence of tumour cavita-
tion on CT scan or X-ray, and no obvious risk of haem-
optysis in the patient’s medical history. One case of
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Figure 1 Kaplan-Meier curve of progression-free survival for the ITT populaaxitinib treatment. Three (7.9%) patients had elevated
systolic BP (≥160 mm Hg) during the study, whereas
none had elevated diastolic BP (≥105 mm Hg). Clinically
significant laboratory abnormalities included elevated
alanine aminotransferase (5.3%) and aspartate amino-
transferase (2.6%), increased blood creatinine (5.3%) and
reduced renal creatinine clearance (13.2%).
Treatment-emergent AEs resulted in at least one dose
interruption in 13 (34.2%) patients, and dose reduction
in five (13.2%) patients. The most frequent reasons for
dose interruption were vomiting and anaemia (n = 3
each [7.9%]) and nausea, fatigue, dyspnoea and hyper-
tension (n = 2 each [5.3%]), whereas the most frequent
reason for dose reduction was hypertension (n = 2
[5.3%]). Overall, eight (21.1%) patients discontinued
treatment due to AEs during the study, with four
(10.5%) patients discontinuing because of drug-related
toxicity (reduced renal creatinine clearance, pulmonary4 3 3 1 1
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Figure 2 Kaplan-Meier curve of overall survival for the ITT population (n = 38). ITT, intent-to-treat.
Table 3 Summary of all-causality adverse events occurring in >2 patients in the ITT population during the study period*
Adverse event Cisplatin + gemcitabine + axitinib (n = 38)
All grades Grade ≥3
No. % No. %
Nausea 16 42.1
Anaemia 12 31.6 3 7.9
Vomiting 11 28.9 2 5.3
Hypertension 10 26.3 5 13.2
Neutropaenia 9 23.7 5 13.2
Weight loss 9 23.7 0 0
Appetite loss 8 21.1 0 0
Fatigue 7 18.4 3 7.9
Asthenia 6 15.8 0 0
Leukopaenia 5 13.2 2 5.3
Diarrhoea 5 13.2 0 0
Reduced creatinine clearance 5 13.2 0 0
Alopecia 5 13.2 0 0
Thrombocytopaenia 4 10.5 0 0
Chest pain 4 10.5 0 0
Toxic nephropathy 4 10.5 0 0
Cough 4 10.5 0 0
Dyspnoea 4 10.5 0 0
Rash 4 10.5 0 0
Pulmonary cavitation 3 7.9 1 2.6
Haemoptysis 3 7.9 1 2.6
ITT = intent-to-treat.
*Study period comprised the treatment period plus 28-day follow-up period after the last dose of study drug.
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each). Four (10.5%) patients died while on treatment
(disease progression, n = 3; cerebrovascular accident and
multiple organ failure, n = 1).
Discussion
This single-arm phase II study demonstrated that the
combination of axitinib with cisplatin/gemcitabine has
anti-tumour activity in advanced/metastatic squamous
NSCLC, as reflected in an objective response rate of
39.5% (95% CI, 24.0–56.6%), a median overall survival of
14.2 months (95% CI, 11.8–23.1 months) and a 1-year
survival rate of 63.2% (95% CI, 44.7–76.9%). The con-
firmed objective response rate (based on investigator
assessment) was, however, only marginally higher than
that previously reported with doublet chemotherapy
(17% to 38%) in advanced NSCLC [4-11] and, accord-
ingly, the null hypothesis that the true response rate is
≤40% was not rejected. The median overall survival of
14.2 months with the combination of axitinib plus
cisplatin/gemcitabine was appreciably higher than most
previously reported results for the doublet chemotherapy
in NSCLC, where median overall survival ranged
between 7.0 and 12.9 months [6-10,36] and was similar
to a previous study where the median overall survival
was 14.0 months with the doublet chemotherapy [8].
The 1-year survival rate of 63.2% appear to be only
marginally higher than the 55.9% [6] and 59.6%% [8] re-
ported previously for cisplatin/gemcitabine treatment.
The toxicities caused by the combination of axitinib
with standard chemotherapy were manageable in this se-
lected patient population. The pattern and frequency of
AEs observed during the study — predominantly nausea,
anaemia, vomiting, hypertension, neutropaenia, weight
loss, decreased appetite and fatigue — were consistent
with the oncology setting and reflect the overall poor
health of patients with advanced/metastatic NSCLC. Of
note, life-threatening pulmonary haemorrhage, which is
a particular safety concern with anti-angiogenic agents
in squamous NSCLC [25], was detected in one (2.6%)
patient who experienced fatal grade 5 haemoptysis
during the first treatment cycle. No risk factors for
haemoptysis were identified in the patient’s medical
history. Although the investigator on site considered
the fatal event not to be related to the study medica-
tions but to NSCLC, it is impossible to rule out the
relationship of axitinib to the development of haemop-
tysis especially given the known risk of haemoptysis
with VEGF inhibitors. In contrast, a randomised phase
II study of bevacizumab, carboplatin and paclitaxel
combination therapy in advanced NSCLC reported
four cases of life-threatening pulmonary haemorrhage
among 13 (30.8%) patients with squamous histology
[26]. The long plasma half-life of bevacizumab may havecontributed to the severity of pulmonary haemorrhage,
since its anti-angiogenic effect cannot be reversed rapidly.
Single-agent tyrosine kinase inhibitors, including
axitinib, have proved to be generally well tolerated in
patients with NSCLC [30,37-40]. The most common
treatment-related AEs reported with axitinib mono-
therapy in NSCLC include fatigue, anorexia, diarrhoea
and nausea, and these can be managed with dose
modification and/or supportive treatment [30]. Although
hypothyroidism has been linked with fatigue as a class
effect of VEGFR-targeted therapy [41], we found no evi-
dence of an increase in thyroid-stimulating hormone
levels during the study. Hypertension, which is commonly
observed with anti-angiogenic agents [42], occurred in
one in four axitinib-treated patients, but was managed
through use of anti-hypertensive treatment or axitinib
dose reduction.
Due to their ability to inhibit multiple angiogenesis
pathways, tyrosine kinase inhibitors offer the potential
for improved efficacy and decreased secondary resistance
[43]. In this study, the combination of axitinib with
cisplatin/gemcitabine provided similar response rate
and median overall survival when compared with
corresponding historical data for cisplatin/gemcitabine
chemotherapy alone. These results are consistent with
previously reported studies of combined chemotherapy
with axitinib [44] and other angiogenic tyrosine kinase
inhibitors in NSCLC [45-47]. A recent randomised
phase II trial of axitinib in combination with pemetrexed/
cisplatin in patients with non-squamous NSCLC showed
that the addition of axitinib resulted in numerically
higher objective response rate but did not significantly
improve median progression-free survival or median
overall survival compared with chemotherapy alone
[44]. The Motesanib NSCLC Efficacy and Tolerability
(MONET1) study, which assessed the effect of adding
motesanib, a small-molecule targeted antagonist of
VEGFR-1, 2 and 3, to doublet chemotherapy (carbopla-
tin and paclitaxel) compared with chemotherapy alone
for first-line therapy of non-squamous NSCLC,
reported a significant improvement in tumour response
rate (40% vs. 26%, respectively), but no benefit in overall
survival (median 13 vs. 11 months, respectively) [47].
Likewise, two randomised phase III trials, Evaluation of
Sorafenib, Carboplatin and Paclitaxel Efficacy (ESCAPE)
and NSCLC Research Experience Using Sorafenib
(NEXUS), found no significant survival benefit from
addition of sorafenib to platinum-based chemotherapy in
unresectable stage IIIb/IV NSCLC [45,46]. Indeed, in
patients with squamous histology, sorafenib appeared to
reduce median overall survival (8.9 vs. 13.7 months,
sorafenib plus chemotherapy vs. chemotherapy alone,
respectively); however, it should be noted that the overall
survival time of patients receiving chemotherapy alone in
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than expected [46]. Similarly, in the phase III Iressa NSCLC
Trial Assessing Combination Treatment (INTACT) 1 and
2 trials, no overall survival benefit was obtained from
addition of the epidermal growth factor tyrosine kinase
inhibitor gefitinib to platinum-based chemotherapy in
chemotherapy-naïve patients with advanced/metastatic
NSCLC [48,49]. The addition of the epidermal growth
factor receptor (EGFR)-directed monoclonal antibody
cetuximab to platinum-based chemotherapy has produced
mixed results in advanced NSCLC, with a significant im-
provement in overall survival being reported in one study
[50] but not replicated in another study [51].
Taken together, these results may suggest that the
combination of chemotherapy plus multi-targeted anti-
angiogenic tyrosine kinase inhibitor therapy may not be
advantageous over chemotherapy alone in terms of over-
all response rate, progression-free survival and overall
survival in advanced NSCLC.
The results of this study should be considered with
respect to its limitations. This was a single-arm study with
a small number of patients. With the lack of a reference
arm (cisplatin/gemcitabine alone), the results were
compared with previous studies and these historical cross-
trial comparisons should be interpreted with caution
because of potential differences in each study, including
the inclusion/exclusion criteria, diagnosis and staging and
other differences [52].
Conclusions
In conclusion, the combination of axitinib with cisplatin
plus gemcitabine demonstrated anti-tumour activity in
patients with advanced/metastatic squamous NSCLC.
Further, the safety profile was consistent with the
oncology setting and reflects the overall poor health of
these patients. Severe pulmonary haemorrhage, a potential
life-threatening toxicity associated with anti-angiogenic
treatment of squamous NSCLC, occurred in one patient.
The study findings provide preliminary indications that
median overall survival in advanced NSCLC can be
extended beyond the 12-month threshold. However, due
to the absence of a reference arm of cisplatin/gemcitabine
alone in this study, it is not conclusive whether the com-
bined treatment is better than chemotherapy alone.
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